Capricor Therapeutics (NASDAQ:CAPR) Stock Price Passes Below 50 Day Moving Average of $4.02

Capricor Therapeutics Inc (NASDAQ:CAPR)’s share price passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $4.02 and traded as low as $2.64. Capricor Therapeutics shares last traded at $2.77, with a volume of 1,528 shares trading hands.

Several analysts have recently weighed in on CAPR shares. Maxim Group reiterated a “hold” rating on shares of Capricor Therapeutics in a research report on Wednesday, August 7th. ValuEngine upgraded shares of Capricor Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research upgraded shares of Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 target price on the stock in a research report on Tuesday, August 13th. Finally, HC Wainwright lifted their target price on shares of Capricor Therapeutics from $3.50 to $12.40 and gave the company a “buy” rating in a research report on Monday, July 15th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $6.63.

The firm’s 50-day moving average price is $3.98 and its two-hundred day moving average price is $1.78.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.21. Capricor Therapeutics had a negative net margin of 794.63% and a negative return on equity of 270.78%. The business had revenue of $0.41 million for the quarter, compared to analyst estimates of $0.22 million. Equities research analysts expect that Capricor Therapeutics Inc will post -2.87 EPS for the current year.

Capricor Therapeutics Company Profile (NASDAQ:CAPR)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

See Also: Does the discount rate affect the economy?

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.